Abstract

Review Article

Faecal Transplant Therapy: A Promising Treatment Modality for Cardiovascular Diseases

K Pushkala and Purshottam D Gupta*

Published: 28 August, 2023 | Volume 8 - Issue 2 | Pages: 108-113

Cardiovascular diseases (CVD) are considered as “lifestyle” diseases and so far “No unified procedure” or medicines are effective in the management of this group of diseases. Researchers and clinicians have indicated that no safe therapeutic window is available in therapeutics at present. Recent research showed that gut microbiota are effective in managing lifestyle diseases therefore we introduced the influence of gut microbiota in the prognosis of the CVDs. Faecal transplant therapy(FMT) has been anticipated to treat many diseases similar to recurrent bacterial Clostridioides difficile infection which has been used worldwide. Recently, FMT was tried on an animal model to treat CVDs, and recent human trials that were tried to manage CVDs in humans by FMT showed encouraging results. The mechanism of action of transplanted bacteria to manage CVDs in the human population is also discussed. In-depth knowledge on the pros and cons of FMT will pave the way to standardize the procedure once the lacuna existing at present in treating CVDs, is paved, this technology will be useful for the masses.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001162 Cite this Article Read Full Article PDF

Keywords:

Atherosclerosis; Arteriosclerosis; Gut microbiota; Experimental models; Mechanisms

References

  1. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Køber L, Torp-Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012 Sep 4;126(10):1185-93. doi: 10.1161/CIRCULATIONAHA.112.114967. Epub 2012 Aug 6. PMID: 22869839.
  2. Qian B, Zhang K, Li Y, Sun K. Update on gut microbiota in cardiovascular diseases. Front Cell Infect Microbiol. 2022 Nov 10;12:1059349. doi: 10.3389/fcimb.2022.1059349. PMID: 36439214; PMCID: PMC9684171.
  3. Arteriosclerosis: Symptoms, Causes & Treatment Cleveland Clinichttps://my.clevelandclinic.org › 24870-arteriosclerosis 04-Apr-2023.
  4. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27;157(1):121-41. doi: 10.1016/j.cell.2014.03.011. PMID: 24679531; PMCID: PMC4056765.
  5. Pushkala K..Faecal transplant technology in therapeutics of Alzheimer's. J. Cell Tissue Res. 2023; 23(20): 73-7325.
  6. Kayama H, Okumura R, Takeda K. Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine. Annu Rev Immunol. 2020 Apr 26;38:23-48. doi: 10.1146/annurev-immunol-070119-115104. PMID: 32340570.
  7. Schiffrin EJ, Blum S. Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S60-4. doi: 10.1038/sj.ejcn.1601489. PMID: 12142966.
  8. Pushkala K. Gupta PD. Management of Huntington’s disease by Faecal Microbiota Transplant (FMT) Technology ( In press).
  9. Pushkala K, Gupta PD. Faecal microbiota transplantation (FMT): An effective therapeutic agent for Parkinson’s disease. 2023. (In press).
  10. Pushkala K, Gupta PD. Faecal microbiota therapy: A promising therapeutic tool for Autism spectrum disorder. 2023. ( In press).
  11. Pushkala K, Gupta PD. Management of obesity and other metabolic disorders through faecal transplant technology. Int J Cell Sci & Mol Biol. 2023; 7(3): IJCSMS:ID555714.
  12. Pushkala K, Gupta PD. Faecal transplant therapy (FMT): A promising therapeutic tool for Diabetes mellitus. ( In press).
  13. Pushkala K, Gupta PD. Polycystic Ovarian Syndrome Managed by Faecal Transplant Therapy. J. Gyne Obste & MotherHealth. 2023; 1: 2: 01-04.
  14. Gupta PD, Pushkala K. FMT as an effective therapeutic agent for Endometriosis. J. Clinical and Medical Case Reports and Reviews. 2023; V(2) : I(2).
  15. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium; Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. doi: 10.1038/nature08821. PMID: 20203603; PMCID: PMC3779803.
  16. Cui D, Tang Y, Jiang Q, Jiang D, Zhang Y, Lv Y, Xu D, Wu J, Xie J, Wen C, Lu L. Follicular Helper T Cells in the Immunopathogenesis of SARS-CoV-2 Infection. Front Immunol. 2021 Sep 16;12:731100. doi: 10.3389/fimmu.2021.731100. PMID: 34603308; PMCID: PMC8481693.
  17. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18. PMID: 25530442; PMCID: PMC4340604.
  18. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol. 1999 Dec;34(7):1975-81. doi: 10.1016/s0735-1097(99)00448-9. PMID: 10588212.
  19. Spence JD. Effects of the intestinal microbiome on constituents of red meat and egg yolks: a new window opens on nutrition and cardiovascular disease. Can J Cardiol. 2014 Feb;30(2):150-1. doi: 10.1016/j.cjca.2013.11.019. PMID: 24461914.
  20. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Bäckhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1(Suppl 1):4592-8. doi: 10.1073/pnas.1011383107. Epub 2010 Oct 11. PMID: 20937873; PMCID: PMC3063583.
  21. Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Bäckhed F, Nielsen J. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. doi: 10.1038/ncomms2266. PMID: 23212374; PMCID: PMC3538954.
  22. Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, Zhang D, Su Z, Fang Z, Lan Z, Li J, Xiao L, Li J, Li R, Li X, Li F, Ren H, Huang Y, Peng Y, Li G, Wen B, Dong B, Chen JY, Geng QS, Zhang ZW, Yang H, Wang J, Wang J, Zhang X, Madsen L, Brix S, Ning G, Xu X, Liu X, Hou Y, Jia H, He K, Kristiansen K. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1. PMID: 29018189; PMCID: PMC5635030.
  23. Liu H, Chen X, Hu X, Niu H, Tian R, Wang H, Pang H, Jiang L, Qiu B, Chen X, Zhang Y, Ma Y, Tang S, Li H, Feng S, Zhang S, Zhang C. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019 Apr 26;7(1):68. doi: 10.1186/s40168-019-0683-9. PMID: 31027508; PMCID: PMC6486680.
  24. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400. PMID: 23614584; PMCID: PMC3701945.
  25. Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, Sartor RB, McIntyre TM, Silverstein RL, Tang WHW, DiDonato JA, Brown JM, Lusis AJ, Hazen SL. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016 Mar 24;165(1):111-124. doi: 10.1016/j.cell.2016.02.011. Epub 2016 Mar 10. PMID: 26972052; PMCID: PMC4862743.
  26. Huynh K. Novel gut microbiota-derived metabolite promotes platelet thrombosis via adrenergic receptor signalling. Nat Rev Cardiol. 2020 May;17(5):265. doi: 10.1038/s41569-020-0367-y. PMID: 32210404.
  27. Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice. Circulation. 2016 Jun 14;133(24):2434-46. doi: 10.1161/CIRCULATIONAHA.115.019645. Epub 2016 Apr 25. PMID: 27143680.
  28. Chan YK, El-Nezami H, Chen Y, Kinnunen K, Kirjavainen PV. Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice. AMB Express. 2016 Dec;6(1):61. doi: 10.1186/s13568-016-0229-5. Epub 2016 Aug 30. PMID: 27576894; PMCID: PMC5005234.
  29. Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W, Weldon R, Auguste K, Yang L, Liu X, Chen L, Yang X, Zhu B, Cai J. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome. 2017 Feb 1;5(1):14. doi: 10.1186/s40168-016-0222-x. PMID: 28143587; PMCID: PMC5286796.
  30. Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics. 2015 Jun;47(6):187-97. doi: 10.1152/physiolgenomics.00136.2014. Epub 2015 Mar 31. PMID: 25829393; PMCID: PMC4451389.
  31. Karbach SH, Schönfelder T, Brandão I, Wilms E, Hörmann N, Jäckel S, Schüler R, Finger S, Knorr M, Lagrange J, Brandt M, Waisman A, Kossmann S, Schäfer K, Münzel T, Reinhardt C, Wenzel P. Gut Microbiota Promote Angiotensin II-Induced Arterial Hypertension and Vascular Dysfunction. J Am Heart Assoc. 2016 Aug 30;5(9):e003698. doi: 10.1161/JAHA.116.003698. PMID: 27577581; PMCID: PMC5079031.
  32. Ge X, Zheng L, Zhuang R, Yu P, Xu Z, Liu G, Xi X, Zhou X, Fan H. The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis. Adv Nutr. 2020 Jan 1;11(1):66-76. doi: 10.1093/advances/nmz064. PMID: 31269204; PMCID: PMC7442397.
  33. Liu J, Li T, Wu H, Shi H, Bai J, Zhao W, Jiang D, Jiang X. Lactobacillus rhamnosus GG strain mitigated the development of obstructive sleep apnea-induced hypertension in a high salt diet via regulating TMAO level and CD4+T cell induced-type I inflammation. Biomed Pharmacother. 2019 Apr;112:108580. doi: 10.1016/j.biopha.2019.01.041. Epub 2019 Feb 18. PMID: 30784906.
  34. Savi M, Bocchi L, Bresciani L, Falco A, Quaini F, Mena P, Brighenti F, Crozier A, Stilli D, Del Rio D. Trimethylamine-N-Oxide (TMAO)-Induced Impairment of Cardiomyocyte Function and the Protective Role of Urolithin B-Glucuronide. Molecules. 2018 Mar 1;23(3):549. doi: 10.3390/molecules23030549. PMID: 29494535; PMCID: PMC6017162.
  35. Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. PMID: 30383184; PMCID: PMC6439564.
  36. Wang G, Kong B, Shuai W, Fu H, Jiang X, Huang H. 3,3-Dimethyl-1-butanol attenuates cardiac remodeling in pressure-overload-induced heart failure mice. J Nutr Biochem. 2020 Apr;78:108341. doi: 10.1016/j.jnutbio.2020.108341. Epub 2020 Jan 9. PMID: 32004931.
  37. Gupta PD, Pushkala K. Fecal Transplant Technology: An Effective Therapeutic Method for Many Diseases. J. Clinical and Medical Case Reports and Reviews. V(2)I(2). 2023.
  38. Kim ES, Yoon BH, Lee SM, Choi M, Kim EH, Lee BW, Kim SY, Pack CG, Sung YH, Baek IJ, Jung CH, Kim TB, Jeong JY, Ha CH. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency. Exp Mol Med. 2022 Feb;54(2):103-114. doi: 10.1038/s12276-022-00728-w. Epub 2022 Feb 3. PMID: 35115674; PMCID: PMC8894390.
  39. Kim TT, Parajuli N, Sung MM, Bairwa SC, Levasseur J, Soltys CM, Wishart DS, Madsen K, Schertzer JD, Dyck JRB. Fecal transplant from resveratrol-fed donors improves glycaemia and cardiovascular features of the metabolic syndrome in mice. Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E511-E519. doi: 10.1152/ajpendo.00471.2017. Epub 2018 Jun 5. PMID: 29870676.
  40. Fåk F, Tremaroli V, Bergström G, Bäckhed F. Oral microbiota in patients with atherosclerosis. Atherosclerosis. 2015 Dec;243(2):573-8. doi: 10.1016/j.atherosclerosis.2015.10.097. Epub 2015 Oct 24. PMID: 26536303.
  41. Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, Hoshi N, Hatano N, Ozawa G, Sasaki N, Mizoguchi T, Amin HZ, Hirota Y, Ogawa W, Yamada T, Hirata KI. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. 2018 Nov 27;138(22):2486-2498. doi: 10.1161/CIRCULATIONAHA.118.033714. PMID: 30571343.
  42. Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkocza B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Koehne G, Barker J, Jakubowski A, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, van den Brink MRM, Giralt SA, Pamer EG, Xavier JB. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018 Sep 26;10(460):eaap9489. doi: 10.1126/scitranslmed.aap9489. PMID: 30257956; PMCID: PMC6468978.
  43. Foye OT, Huang IF, Chiou CC, Walker WA, Shi HN. Early administration of probiotic Lactobacillus acidophilus and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling. FEMS Immunol Med Microbiol. 2012 Aug;65(3):467-80. doi: 10.1111/j.1574-695X.2012.00978.x. Epub 2012 May 25. PMID: 22524476; PMCID: PMC4015462.
  44. Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, Li M, Sun L, Xue Z, Wang J, Feng J, Yan F, Zhao N, Liu J, Long W, Zhao L. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014 Feb;87(2):357-67. doi: 10.1111/1574-6941.12228. Epub 2013 Oct 21. PMID: 24117923; PMCID: PMC4255291.
  45. Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A, Mackay CR, Kaye DM. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation. 2017 Mar 7;135(10):964-977. doi: 10.1161/CIRCULATIONAHA.116.024545. Epub 2016 Dec 7. PMID: 27927713.
  46. Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):675-82. doi: 10.1517/17425250902973695. PMID: 19442033.
  47. Chi C, Li C, Wu D, Buys N, Wang W, Fan H, Sun J. Effects of Probiotics on Patients with Hypertension: a Systematic Review and Meta-Analysis. Curr Hypertens Rep. 2020 Mar 21;22(5):34. doi: 10.1007/s11906-020-01042-4. PMID: 32200440.
  48. Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman NH, Baker JE. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012 Apr;26(4):1727-35. doi: 10.1096/fj.11-197921. Epub 2012 Jan 12. PMID: 22247331; PMCID: PMC3316900.
  49. Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, Sidaway JE, Martin G, Gloor GB, Swann JR, Reid G, Karmazyn M. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail. 2014 May;7(3):491-9. doi: 10.1161/CIRCHEARTFAILURE.113.000978. Epub 2014 Mar 13. PMID: 24625365.
  50. Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol. 2015 Jan 20;179:348-50. doi: 10.1016/j.ijcard.2014.11.034. Epub 2014 Nov 11. PMID: 25464484.
  51. Chen ML, Yi L, Zhang Y, Zhou X, Ran L, Yang J, Zhu JD, Zhang QY, Mi MT. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. mBio. 2016 Apr 5;7(2):e02210-15. doi: 10.1128/mBio.02210-15. PMID: 27048804; PMCID: PMC4817264.
  52. Anlu W, Dongcheng C, He Z, Qiuyi L, Yan Z, Yu Q, Hao X, Keji C. Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. Pharmacol Res. 2019 Apr;142:205-222. doi: 10.1016/j.phrs.2019.02.018. Epub 2019 Feb 19. PMID: 30794922.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?